← Back to Search

Monoclonal Antibodies

Cosibelimab + Ublituximab + Bendamustine combination for Non-Hodgkin's Lymphoma

Phase 1
Waitlist Available
Research Sponsored by TG Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights

Summary

This study is evaluating whether a new treatment may help individuals with Hodgkin's lymphoma.

Eligible Conditions
  • Richter's Transformation
  • Non-Hodgkin's Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events That Are Related to Treatment
Secondary outcome measures
Overall Response Rate

Trial Design

3Treatment groups
Experimental Treatment
Group I: Cohort CExperimental Treatment1 Intervention
Cosibelimab + Ublituximab + Bendamustine combination
Group II: Cohort BExperimental Treatment1 Intervention
Cosibelimab + Ublituximab + Bendamustine combination
Group III: Cohort AExperimental Treatment1 Intervention
Cosibelimab (TG-1501) single-agent

Find a Location

Who is running the clinical trial?

TG Therapeutics, Inc.Lead Sponsor
38 Previous Clinical Trials
6,847 Total Patients Enrolled
~3 spots leftby Jul 2025